Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Clin Cancer Res. 2008 Oct 1;14(19):6343–6349. doi: 10.1158/1078-0432.CCR-08-1198

Table 4.

Frequencies of inferred haplotypes and diplotypes of CASP3 based on the observed genotypes in SCCHN cases and cancer-free control

Cases Controls Crude OR Adjusted OR*
No. (%) No. (%)
Haplotypes N=1860 N=1986
 GCG 705 (37.9) 814 (41.0) 1.00 1.00
 TCG 759 (40.8) 745 (37.5) 1.18 (1.02, 1.36) 1.18 (1.02-1.37)
 GCA 229 (12.3) 215 (10.9) 1.25 (1.01, 1.56) 1.21 (0.96-1.51)
 MAF<0.1 167 (8.97) 211 (10.6) 0.89 (0.70, 1.11) 0.92 (0.72-1.17)
P value 0.024 0.017 0.050§
Diplotype N=930 N=993
 0 227 (24.4) 277 (27.9) 1.00 1.00
 1 398 (42.8) 448 (45.1) 1.08 (0.87-1.35) 1.06 (0.84-1.34)
 2 305 (32.8) 268 (27.0) 1.39 (1.09-1.77) 1.36 (1.06-1.75)
 0 or 1 625 (67.2) 725 (73.0) 1.00 1.00
 2 305 (32.8) 268 (27.0) 1.32 (1.09-1.61) 1.31 (1.07-1.61)
*

Adjusted for sex, age, smoking status and alcohol use in a logistic regression model.

Pearson’s χ2-test were used to test for the difference in the distribution of all haplotypes/diplotypes between cases and controls.

Likelihood ratio test for the significance of haplotypes associated with SCCHN risk.

§

Likelihood ratio test for haplotypes effect with adjustment for sex, age, smoking status and alcohol use.

Diplotype was coded as 0 if there was no TCG or GCA in the haplotype pair; 1 if there was only one copy of TCG or GCA in the haplotype pair; and 2 if there were 2 copies of TCG or GCA in the haplotype pair.